23 Noonan syndrome (NS) is caused by mutations in RAS/ERK pathway genes, and 24 is characterized by craniofacial, growth, cognitive and cardiac defects. NS patients with 25 kinase-activating RAF1 alleles typically develop pathological left ventricular hypertrophy 26 (LVH), which is reproduced in Raf1 L613V/+ knock-in mice. Here, using inducible Raf1 L613V 27 expression, we show that LVH results from the interplay of cardiac cell types. 28 Cardiomyocyte Raf1 L613V enhances Ca 2+ sensitivity and cardiac contractility without 29 causing hypertrophy. Raf1 L613V expression in cardiomyocytes or activated fibroblasts 30 exacerbates pressure overload-evoked fibrosis. Endothelial/endocardial (EC) Raf1 L613V 31 causes cardiac hypertrophy without affecting contractility. Co-culture and neutralizing 32 antibody experiments reveal a cytokine (TNF/IL6) hierarchy in Raf1 L613V -expressing ECs 33 that drives cardiomyocyte hypertrophy in vitro. Furthermore, post-natal TNF inhibition 34 normalizes the increased wall thickness and cardiomyocyte hypertrophy in vivo. We 35 conclude that NS cardiomyopathy involves cardiomyocytes, ECs, and fibroblasts, 36 TNF/IL6 signaling components represent potential therapeutic targets, and abnormal EC 37 signaling might contribute to other forms of LVH. 38 39 RASopathy, Noonan Syndrome (NS), can be caused by germ-line gain-of-function 57 PTPN11, KRAS, NRAS, RRAS, SHOC2, SOS1/2, RAF1, RIT1 or PPP1CB alleles 12,15-20 . 58 Pathological LVH (NS-cardiomyopathy) is seen in ~20% of NS cases overall. Kinase 59 activating mutations in RAF1, which encodes a serine/threonine kinase for MEK, account 60 for a small fraction (~5%) of NS, but nearly all (>95%) such patients develop NS-61 cardiomyopathy 21 . Previously, we found that Raf1 L613V/+ knock-in mice recapitulate the 62 4 human disorder, with growth defects, facial dysmorphia, and most importantly, eccentric 63 LVH 22 . Specifically, in Raf1 L613V/+ knock-in mice, heart mass, ventricular wall thickness, 64 ventricular chamber dimensions and cardiac contractility are increased, and cardiac 65 fibrosis following pressure overload is exacerbated. 66 Capitalizing on our inducible Raf1 L613V allele (Raf1 L613Vfl ) 22 , we deconstructed the 67 above cardiac phenotypes into their contributing cell types. Surprisingly, although 68 expression of mutant Raf1 in CMs caused altered contractility as a consequence of 69 increased calcium sensitivity, it did not result in pathological LVH. Mutant expression in 70 activated cardiac fibroblasts or CMs resulted in an increased fibrotic response to pressure 71 overload. Intriguingly, mutant expression in ECs, by means of a TNF/IL6 cytokine 72 hierarchy, led to increased CM and chamber size without affecting contractility. 73 Treatment of Raf1 mutant mice with anti-TNF antibodies reversed their increased CM 74 size and wall thickness. Our results reveal the cellular and molecular complexity 75 underlying NS cardiomyopathy and suggest that anti-TNF antibodies could be a 76 therapeutic option for severe pathological LVH in NS patients. 77 78 Results 79
Introduction 40
Pathological left ventricular hypertrophy (LVH) is a common inherited disorder 41 (~1 in 500 live births), and represents the leading cause of sudden death in young 42 people 1-3 . Features of pathological hypertrophy include increased cardiomyocyte (CM) 43 size, thickening of the ventricular wall and septum, perivascular and interstitial fibrosis, 44 and cardiac dysfunction that can eventuate in heart failure 2,3 . LVH has many potential 45 etiologies, including hypertension, cardiac valve disease or genetic defects 4-6 . Most 46 inherited forms of LVH are caused by mutations in genes encoding sarcomeric 47 proteins 1,3,5,7 ; hence, most studies of these disorders have focused on the CM-intrinsic 48 effects of these genes. However, ~25% of cases are caused by mutations in genes that 49 encode signal transduction components. Genetic analyses and transgenic animal models 50 have confirmed that aberrant signaling can drive pathological cardiac hypertrophy, often 51 in association with other systemic defects [8] [9] [10] [11] . 52
Abnormal regulation of the RAS/RAF/MEK/ERK (hereafter, RAS/ERK) pathway 53 underlies a group of related developmental syndromes termed "RASopathies", which are 54 characterized by a spectrum of phenotypes, including craniofacial dysmorphia, delayed 55 growth, cognitive problems and cardiac abnormalities [12] [13] [14] . The most common 56 cassette in the Raf1 L613V allele had been excised efficiently in the hearts of 10 week-old 86 mice (compare to global Raf1 L613V/+ mice; Supplementary Fig. 1b ), as well as in isolated 87
CMs at post-natal day 4 ( Supplementary Fig. 1c) . Surprisingly, and in stark contrast to 88 global Raf1 L613V/+ mice, heart weight to body weight (HW/BW) ratio and CM cross-89 sectional area in Mlc2v-L613V mice were comparable to littermate controls (Fig. 1b, c) . 90
Similarly, HW/BW ratio was not increased (and in fact, was slightly decreased) when 91 Raf1 L613V expression was induced in atrial and ventricular myocardium under the control 92 of the cardiac troponin T promoter 24 ( Supplementary Fig. 1d ). Echocardiography, 93 performed at 16 weeks of age, revealed reduced left ventricular internal end-systolic 94 (LVIDs) and -diastolic (LVIDd) dimensions ( Fig. 1d, e ) and a small increase in left 95 ventricular posterior wall thickness (LVPWd; Fig. 1f ) in Mlc2v-L613V hearts. 96
Although Mlc2v-L613V hearts showed minimal hypertrophy, they were markedly 97 hyper-contractile. As in global Raf1 L613V/+ mice, ejection fraction (EF) and fractional 98 shortening (FS) were increased in Mlc2v-L613V mice, compared with controls 99
( Supplementary Table 1 ). Invasive hemodynamics revealed increased dP/dt max and 100 dP/dt@LVP40 (Fig. 1g) ; the latter is independent of the slightly reduced afterload 101 (systolic pressure) observed in these mice ( Supplementary Table 2 ). Thus, CM-restricted 102 RAF1 mutant expression induces a hyper-contractile state in the absence of CM 103 hypertrophy. 104
To ask whether the effects of the RAF1 mutant on cardiac contractility originated 105 from alterations in Ca 2+ homeostasis, we loaded CMs isolated from Mlc2v-control or -106 L613V mice with Fura-2 and measured Ca 2+ transients (i.e., R 340/380 ) in response to field 107 stimulation at 0.5 Hz. Representative Ca 2+ transients were similar in freshly isolated 108 single Mlc2v-control and -L613V CMs ( Supplementary Fig. 2a ). Neither basal Ca 2+ 109 levels, nor the Ca 2+ transient peaks, differed between the groups ( Supplementary Fig. 2b : 110 basal R 340/380 was 1.00 ± 0.02 for Mlc2v-control vs. 1.03 ± 0.02 for Mlc2v-L613V, P = 111 0.24, Student's t test; peak R 340/380 was 1.82 ± 0.05 for Mlc2v-control vs. 1.81 ± 0.05 for 112
Mlc2v-L613V, P = 0.90, Student's t test). Likewise, no differences were observed in the 113 kinetics of the Ca 2+ transients ( Supplementary Fig 2c: time to the R 340/380 peak 47.72 ± 114 2.57 ms in Mlc2v-control vs. 46.12 ± 2.36 ms in Mlc2v-L613V, P = 0.65, Student's t 115 test; time to 50% decay of the R 340/380 was 218.17 ± 8.07 ms for Mlc2v-control vs. 210.62 116 ± 9.36 ms for Mlc2v-L613V, P=0.55, Student's t test). Quantitative reverse-transcription 117 PCR (qRT-PCR) and immunoblots of lysates from Mlc2v-L613V hearts showed similar 118 levels of SERCA mRNA and protein, respectively, as in littermate control hearts 119 ( Supplementary Fig. 2d , e and 9). 120 Enhanced cardiac contractility in Mlc2v-L613V mice in the absence of elevated 121 intracellular Ca 2+ levels might reflect increased Ca 2+ -sensitivity of the contractile 122 apparatus. We assessed Ca 2+ sensitivity by determining the relationship between force 123 and Ca 2+ during twitches induced by field stimulation of isolated CMs attached to stiff 124 glass rods ( Supplementary Fig. 3 ) 25, 26 . Plots of force as a function of Ca 2+ (phase plots 25 ) 125 during the very late phase of the force relaxation curve became independent of peak force 126 levels when CMs were held at a resting sarcomere length of 1.8 µm ( Supplementary Fig.  127 4). Hence, the force-Ca 2+ relationship achieves a steady state during the terminal phase of 128 relaxation, which enables assessment of the Ca 2+ sensitivity of CM contractile proteins 25 . 129
Typical simultaneous force-Ca 2+ recordings for Mlc2v-control and -L613V CMs revealed 130 comparable decay kinetics of the Ca 2+ transient (solid lines) in both groups, but the force 131 comparable to those co-cultured with control CD90 + cells ( Supplementary Fig. 5b ); under 154 the same conditions, mutant ECs promote CM hypertrophy in vitro (see below). 155 FSP1 expression is induced in activated cardiac (and other) fibroblasts upon stress 156 ( Supplementary Fig. 5a ) 27, 28 . Indeed, compared with controls, Fsp1-L613V mice 157 developed more severe interstitial fibrosis within two weeks of biomechanical stress 158 imposed by transverse aortic constriction (TAC; Fig. 3e Supplementary Fig. 1c ) was associated 180 with marked cardiac hypertrophy both basally ( Fig. 4a , b) and following TAC (Fig. 3i, j) , 181 as indicated by significant increases in HW/BW ratio and CM cross-sectional area. 182
Cardiac hypertrophy was detectable as early as post-natal day 4 ( Supplementary Fig. 6a , 183 b), but there was no difference in the number of BrdU + (proliferation) or TUNEL + 184 (apoptosis) CMs in embryonic Tie2-L613V or Nfatc1-L613V hearts ( Supplementary Fig.  185 6c, d). Valvuloseptal development and function were normal, as assessed by histology 186 ( Supplementary Fig. 6e ) and by the absence of a significant pressure gradient across the 187 aortic valve ( Supplementary Table 2 ). Systemic arterial pressure was lower in Tie2-188 L613V or Nfatc1-L613V mice than in controls ( Supplementary Table 2 ), excluding 189 hypertension as the cause of cardiac hypertrophy. Echocardiograms revealed markedly 190 increased LVIDs and LVIDd ( Fig. 4c, d) , along with increased LVPWd (Fig. 4e ). 191
Remarkably, contractility remained within normal limits, as assessed by 192 echocardiography and invasive hemodynamic analysis ( Fig. 4f and Supplementary Table  193 1, 2). Even when subjected to TAC, cardiac contractility in Tie2-L613V mice remained 194 comparable to littermate controls (Fig. 3g paracrine signals 31 . To explore the non-cell autonomous effects of 201 endocardium/endothelium on CM hypertrophy, we purified RAF1 mutant or control 202 cardiac endothelial/endocardial cells with CD31 magnetic beads, and co-cultured them 203 with wild type neonatal CMs in serum-free media conditions ( Fig. 5a ). Consistent with 204 our in vivo findings, CM surface area was increased after three days of co-culture with 205
Tie2-L613V or Nfatc1-L613V ECs, compared with those co-cultured with controls ( Fig.  206 5b and Supplementary Fig. 7a ). RAF1 mutant CMs exhibited similar increases in cell size 207 to control CMs after co-culture with RAF1 mutant ECs, confirming that signals 208 emanating from ECs are the primary cause of CM hypertrophy ( Supplementary Fig. 7b ). 209
A similar size increase occurred in Transwell assays (Fig. 5a , c), suggesting that (a) 210 diffusible, paracrine factor(s) derived from RAF1 mutant ECs promotes CM hypertrophy. 211
To search for this paracrine factor(s), we screened conditioned media from Tie2-212 L613V or control ECs for multiple cytokines, including known inducers of cardiac 213 hypertrophy ( Supplementary Fig. 7c ). We observed 1.5-2 fold increases in the levels of 214 Tumor Necrosis Factor alpha (TNF) and interleukin-6 (IL6) in conditioned media from 215 mutant ECs (Fig. 5d ). The Tnf promoter contains Activator protein-1 (AP-1) and ETS-1 216 (transcription factors downstream of ERK) binding sites 32,33 , and RNAseq analysis 217 revealed increased transcripts of Tnf (among other genes) in mutant ECs (Supplementary 218 Fig. 7d ). We confirmed this finding by using qRT-PCR ( Fig. 5e ). By contrast, the 219 increased IL6 production reflected post-transcriptional regulation ( Supplementary Fig.  220 7e). The isolated CD31 + population contained almost no CD45 + cells (Supplementary 221 Fig. 7f ), and heart sections from Tie2-L613V mice exhibited comparable CD45 staining 222 to their littermate controls ( Supplementary Fig. 7g ), arguing against contaminating 223 hematopoietic cells as the source of the increased TNF and IL6 in EC-conditioned media. 224
Addition of recombinant mouse TNF or IL6 (at levels similar to those found in 225 RAF1 mutant EC-conditioned media) induced dose-dependent increases in wild type CM 226 size ( Supplementary Fig. 8a, b ). Furthermore, neutralizing anti-TNF or anti-IL6 227 monoclonal antibodies (but not cognate isotype-matched controls) blocked the pro-228 hypertrophic effects of RAF1 mutant ECs on co-cultured CMs. As expected, the effects 229 of each neutralizing antibody were reversed by adding an excess of the cognate 230 exogenous cytokine ( Fig. 5f , g). These data argue that TNF/IL6 produced by mutant 231 cardiac ECs play a critical role in the development of cardiomyopathy in RAF1-mutant 232
NS. 233
In many inflammatory disorders, most notably, rheumatoid arthritis, TNF stands 234 atop a cytokine hierarchy that can include IL6 34, 35 . An analogous hierarchy appears to be 235 present in RAF1-mutant ECs: TNF increased, whereas anti-TNF antibody treatment 236 decreased the levels of IL6 in cardiac EC-conditioned media ( Supplementary Fig. 8c ). 237 Furthermore, the hypertrophy-reducing effects of the neutralizing anti-TNF antibody 238 were reversed by excess IL6, as well as by TNF, placing IL6 production "downstream" of 239 TNF stimulation ( Fig. 5f ). IL6 signals via the IL6 receptor/gp130 complex, which in 240 turn, activates the JAK/STAT, MEK/ERK and PI3K/AKT pathways. Consistent with IL6 241 acting as the proximate mediator of HCM in vivo, immunoblots of total heart extracts 242 from Tie2-L613V mice, which express mutant RAF1 only in ECs but predominantly 243 contain CM-derived proteins, revealed increased activation of STAT3 (phospho (p)-244 Tyr705) and STAT5 (p-Tyr694), MEK (p-Ser217/221), ERK (p-Tyr204Thr202) and 245 AKT (p-Ser473 and p-Thr308; Fig. 5h , Supplementary Fig. 8d -I, 10 and 11), compared 246 with control hearts. 247
248

CM hypertrophy is normalized by TNF inhibition in vivo 249
Our co-culture experiments implicated EC-derived TNF in the pathogenesis of 250 CM hypertrophy. We therefore asked if TNF inhibition could normalize EC-induced CM 251 hypertrophy in vivo. Tie2-L613V or littermate control mice (4 week-old) were injected 252 i.p. with anti-TNF neutralizing antibody or isotype control (5 mg/kg body weight) twice 253 weekly for 6 weeks (Fig. 6a ). Ventricular chamber dimensions and HW/BW ratio 254 remained elevated in Tie2-L613V mice after 6 weeks of anti-TNF antibody treatment 255 ( Supplementary Fig. 8j TNF antibody-treated Tie2-L613V mice, compared with isotype control-treated 257 mice ( Fig. 6b ). We also observed a corresponding decrease in CM cross-sectional area in 258
Tie2-L613V mice subjected to TNF inhibition ( Fig. 6c ). Notably, hearts from wild type 259 littermates were not affected by anti-TNF antibody treatment, indicating that antibody 260 effects are RAF1 mutant-specific. Furthermore, cardiac function was preserved in Tie2-261 L613V mice subjected to anti-TNF antibody therapy ( Fig. 6d, e ). Interestingly, the 262 decreased blood pressure in Tie2-L613V mice also was normalized by anti-TNF 263 treatment (LVP was 97.3 ± 2.4 mmHg in Tie2-L613V mice with isotype control 264 treatment vs. 107.9 ± 0.9 mmHg in those with TNF inhibition). 265
266
Discussion 267
We find that combinatorial interactions of CMs, ECs and cardiac fibroblasts 268 underlie the pathogenesis of RAF1 mutant NS-associated cardiomyopathy (Fig. 6f ). In 269 line with the conventional view, altered cardiac contractility in this setting arises from a 270 CM-intrinsic defect(s) that causes increased sensitivity of the cardiac contractile 271 apparatus to Ca 2+ . But although CM-specific mutant RAF1 expression slightly increases 272 ventricular wall thickness, the major pro-hypertrophic signals, including TNF (and IL6), CMs derived from BRAF mutant human induced pluripotent 283 cells (hiPSCs) from patients with cardio-facial-cutaneous syndrome also have increased 284 calcium transients 44 . Conversely, we find that a NS-associated activating RAF1 mutant, 285 when expressed solely in CMs, does not affect Ca 2+ levels, but instead, increases the Ca 2+ 286 sensitivity of the contractile apparatus. We observe a similar alteration in calcium 287 sensitivity in RAF1 mutant human CMs derived from hiPSCs or ESCs (T. Araki, 288 unpublished observations). Precisely how mutant RAF1 regulates Ca 2 + sensitivity 289 remains to be elucidated, although it likely involves altered phosphorylation of key 290 calcium handling or myofilament proteins 45, 46 . Taken together, though, these finding 291 suggest that different RASopathy mutations might alter CM contractility in distinct ways. 292 Surprisingly, mutant RAF1 expression in CM causes minimal hypertrophy. By 293 contrast, EC-restricted mutant expression does not affect contractility, but evokes 294 hypertrophy. Excess TNF produced by mutant ECs can, via a cytokine hierarchy that 295 includes IL6 and probably other agonists, account for their pro-hypertrophic effects in 296 vitro (i.e., co-culture/Transwell assays). Interfering with TNF action (by neutralizing 297 antibody injections) also normalizes the increased ventricular wall thickness and CM size 298 in vivo. Reverse remodeling is not complete, however, as chamber size and HW/BW 299 remain elevated. Notably, complete remodeling is possible, as MEK inhibitor treatment 300 fully reverses pathological hypertrophy in global Raf1 L613V/+ mice 22 . 301
Failure of anti-TNF therapy to restore normal cardiac chamber size presumably 302 reflects other, TNF-independent, paracrine signals from mutant ECs. Matrix 303 metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and ADAMs 304 are implicated in pathological cardiac hypertrophy 47,48 , and several of these are 305 dysregulated in RAF1 mutant ECs ( Supplementary Fig. 7d ). Although TNF stimulates 306 production of some MMPs, most MMP promoters contain AP-1 and/or PEA3 elements 307 and could be stimulated directly by ERK-catalyzed phosphorylation 47 . Alternatively, 308 TNF could have a "Goldilocks" effect, with too much or too little having deleterious 309 consequences, and our anti-TNF therapy might have been insufficient to restore normal 310 cardiac size. Indeed, increased TNF levels are seen in patients with HCM and other 311 cardiac disorders 49-55 . However, results from large clinical trials, as well as several case 312 reports, suggest that too much TNF inhibition can lead to dilated cardiomyopathy and/or 313 heart failure [56] [57] [58] [59] . Notably, cardiac function is preserved in our TNF antibody-treated 314 mice. Nevertheless, future studies will be needed to determine the effect of TNF 315 inhibition on all of the paracrine signaling molecules altered in RAF1 mutant ECs and to 316 assess the dose-response relationship between TNF inhibition and cardiac hypertrophy. 317
Increasing evidence points to the importance of communication between 318 myocytes and non-myocytes in modulating cardiac function and structure under 319 physiological and pathological conditions 31 Freshly isolated ventricular CMs were loaded with Fura-2 as described above. 435
CMs were attached to a pair of glass rods using the biocompatible adhesive MyoTak 436 (World Precision Instruments, Inc.), as per the manufacturer's directions. After 437 "adhesion", CMs were lifted from the glass and were field stimulated at various rates 438 (0.1-10 Hz) using 2 ms pulses at twice the threshold voltage (typically 10 V/cm). During 439 recording of force and Ca 2+ transients myocytes were illuminated using red light (650-440 690 nm). Light (510 nm plus 650-690 nm) was collected with a 40X objective 441 Hearts from 10 to 16-week old mice were harvested and flash frozen in liquid 524 nitrogen. For Ca 2+ handling proteins, total protein extracts from hearts were prepared by 525 homogenization in 1% SDS (50 mM Tris-HCl, pH 8, 100 mM NaCl, 2 mM EDTA). For 526 signaling proteins, total protein extracts from hearts were prepared by homogenization in 527 RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% 528 Na deoxycholate, and 0.1% SDS), containing a protease and phosphatase inhibitor 529 cocktail (40 μ g/ml PMSF, 20 mM NaF, 1 mM Na 3 VO 4 , 10 mM β -glycerophosphate, 10 530 mM sodium pyrophosphate, 2 μ g/ml antipain, 2 μ g/ml pepstatin A, 20 μ g/ml leupeptin, 531 and 20 μ g/ml aprotinin). Lysates were centrifuged at 16,100 g for 15 minutes at 4 °C. 532
Clarified supernatants (70 μ g for detection of pSTAT3 and pSTAT5; 10-25 μ g for others) 533
were resolved by SDS-PAGE and analyzed by immunoblotting. Antibodies used for 534 immunoblots included: anti-ERK2 (7 ng/ml, Clone D-2; Santa Cruz Biotechnology Inc.), 535 For cell culture experiments, sample size was not pre-determined, and all samples were 561 included in analysis. All data are presented as mean ± standard error of the means 562 (S.E.M.). For normally distributed data, differences between two groups were evaluated 563 by Student's t test and differences between multiple groups were evaluated by ANOVA, 564 followed by Bonferroni's post-test. For non-normally distributed data (Fig. 5b , c, f, and 565 g), differences between two groups were evaluated with the non-parametric Whitney test and differences between multiple groups were evaluated by the non-567 parametric Kruskal-Wallis one-way analysis of variance (ANOVA), followed by Dunn's 568 post-hoc test. For all experiments, except for cell culture experiments (Fig. 5b , c, f, and 569 g), the between-group variances were similar and data were symmetrically distributed. 570
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